EVANSTON, Ill.--(Business Wire)--
Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that it has
terminated the employment of substantially all of its operational and staff
employees at its manufacturing facility in Mount Prospect, Illinois and
headquarters in Evanston, Illinois.
The Company is evaluating future options for the Company and its business.
About Northfield Laboratories
Northfield Laboratories is developing a hemoglobin-based oxygen-carrying red
blood cell substitute, PolyHeme. PolyHeme is a solution of chemically modified
human hemoglobin that requires no cross-matching and is therefore compatible
with all blood types. It has an extended shelf life in excess of 12 months. For
further information, visit http://www.northfieldlabs.com.
Forward Looking Statement
This press release may contain forward-looking statements concerning, among
other things, Northfield's future business plans and strategies and clinical and
regulatory developments affecting our PolyHeme red blood cell substitute
product. These forward-looking statements are identified by the use of such
terms as "intends," "expects," "plans," "estimates," "anticipates," "should,"
"believes" and similar terms. These forward-looking statements involve inherent
risks and uncertainties. Our actual results may therefore differ materially from
those predicted by the forward-looking statements because of various factors and
possible events, our potential inability to obtain FDA approval to market
PolyHeme commercially based on our BLA,our potential inability to obtain
adequate additional capital to continue our business, our potential inability to
maintain compliance with applicable Nasdaq listing standards, our potential
inability to obtain adequate supplies of raw materials and to manufacture
PolyHeme in commercial quantities, our potential inability to market PolyHeme
successfully, the possibility that competitors will develop products that will
render PolyHeme obsolete or non-competitive, our potential inability to protect
our intellectual property rights, the outcome of a purported class action
lawsuit as described in our most recently filed quarterly report on Form 10-Q,
the possibility that we may be subject to product liability claims and other
legal actions, our dependency on a limited number of key personnel, the
uncertainty of third party reimbursement for our product and other risks and
uncertainties described from time to time in our periodic reports filed with the
Securities and Exchange Commission, including our most recently filed annual
report on Form 10-K and quarterly report onForm 10-Q. These forward-looking
statements speak only as of the date of this press release. We do not undertake
any obligation to update or publicly release any revisions to forward-looking
statements to reflect events, circumstances or changes in expectations after the
time such statement is made. All subsequent written and oral forward-looking
statements attributable to Northfield or any person acting on our behalf are
qualified by this cautionary statement.
Northfield Laboratories Inc.
Sophia H. Twaddell, 847-864-3500
Vice President, Corporate Communications
stwaddell@northfieldlabs.com
Copyright Business Wire 2009
